Key result
Novel loss-of-function TBX20 truncating variants are identified in ~0.6% of patients with sporadic AF.
Why the study?
TBX20 mutations contribute to familial AF, but the mutational prevalence and spectrum of this gene in sporadic AF remain unknown.
Are TBX20 variations associated with an increased susceptibility to sporadic atrial fibrillation?
Case-Control (n=728)
Are TBX20 variations associated with an increased susceptibility to sporadic atrial fibrillation?
The identification of two novel loss-of-function TBX20 variations in patients with sporadic atrial fibrillation provides first evidence that genetically defective TBX20 enhances susceptibility to sporadic AF via a haploinsufficiency mechanism.
Answers are grounded in this paper and cite their sources.
TBX20 truncating variants may predispose to sporadic AF; extends familial data but remains hypothesis-generating.
Background/Objectives: Atrial fibrillation (AF), the most prevalent form of clinical cardiac arrhythmia globally, is associated with markedly increased morbidity, mortality, and socio-economic expenditure. Accumulating strong evidence highlights genetic abnormalities underpinning its etiopathogenesis. A recent investigation has demonstrated that mutations in the TBX20 gene, which codes for a T-box transcription factor essential for proper cardiovascular development and structural remodeling, contribute to familial AF. Nevertheless, the mutational prevalence and spectrum of this gene in patients with sporadic AF remain unknown. Methods: A cohort of 352 individuals suffering from sporadic AF and a group of 376 healthy subjects without AF history were recruited prospectively. Sanger sequencing examination of TBX20 was implemented in all research participants. The functional impacts of the discovered TBX20 variations were quantitatively measured by dual-reporter gene analysis. Results: Two novel heterozygous truncating TBX20 variations, NM_001077653.2: c.725C>A; p.(Ser242*) and NM_001077653.2: c.826A>T; p.(Lys276*), were detected in two of the 352 cases with sporadic AF, respectively, with a mutational prevalence of approximately 0.57%. The two TBX20 variants were absent from the 752 control chromosomes. Functional measurements revealed that both Ser242* and Lys276* variants lost transactivation on KCNH2 and NPPA, two genes responsible for AF. In addition, each of the two variations abrogated the synergistic transactivation of NPPA by TBX20 together with NKX2.5, another gene reported to cause AF. Conclusions: The current data indicate haplo-insufficient TBX20 variations as new genetic defects predisposing to sporadic AF and hence are conducive to improving the prophylaxis and treatment strategies of sporadic AF in a subset of patients.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) conducted a case-control in Sporadic Atrial Fibrillation (n=728). TBX20 gene variations vs. Healthy subjects without AF history (wild-type TBX20) was evaluated on Prevalence of TBX20 variations. Two novel heterozygous truncating TBX20 variations were identified in 0.57% of patients with sporadic atrial fibrillation and were absent in healthy controls, demonstrating loss of transactivation on KCNH2 and NPPA.
Synapse has enriched 10 related papers. Consider them for comparative context: